Bamba Vaneeta
Division of Endocrinology and Diabetes, The Children's Hospital of Philadelphia and The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104.
J Clin Endocrinol Metab. 2014 Sep;99(9):3093-102. doi: 10.1210/jc.2013-3860. Epub 2014 May 21.
Cardiovascular disease is a leading cause of morbidity and mortality. Early identification and treatment of risk factors that accelerate this condition are paramount to preventing disease. To this effect, the National Heart Lung and Blood Institute (NHLBI), endorsed by the American Academy of Pediatrics, issued updated pediatric guidelines for cardiovascular risk reduction in 2011. Integration of these guidelines into pediatric practice may lessen cardiovascular morbidity.
In addition to reviewing the NHLBI guidelines, a detailed literature search was performed on PubMed for clinical studies published between 2010 and 2013. Key search terms included "pediatric dyslipidemia/hyperlipidemia," "cardiovascular disease," "atherosclerosis," "familial hypercholesterolemia," "hypertriglyceridemia," and "diabetes." Additional citations from these publications were also reviewed. Final publications were selected for their relevance to the topic.
These guidelines contain several important recommendations relative to lipid management, including screening all children with nonfasting non-high-density lipoprotein-cholesterol at ages 9-11 years, incorporation of aggressive lifestyle changes to meet cholesterol targets, and initiation of statin therapy for those with low-density lipoprotein-cholesterol elevation. In addition, both type 1 and type 2 diabetes are now considered high-risk conditions and have stringent cholesterol targets. The primary aim is early identification of children with familial hypercholesterolemia; however, these recommendations have met with some controversy. The purpose of this update is to summarize these recent lipid guidelines, present the relevant controversies, highlight common cholesterol disorders, and discuss dyslipidemia specific to the pediatric diabetes population.
Identification and treatment of youth with dyslipidemia is of paramount importance to the reduction of future cardiovascular disease. Increasing the comprehension and application of the newest NHLBI guidelines is critical to improving cardiovascular outcomes.
心血管疾病是发病和死亡的主要原因。尽早识别并治疗加速病情发展的风险因素对于预防疾病至关重要。为此,在美国儿科学会认可下,美国国立心肺血液研究所(NHLBI)于2011年发布了最新的儿童心血管疾病风险降低指南。将这些指南纳入儿科临床实践可能会降低心血管疾病的发病率。
除了回顾NHLBI指南外,还在PubMed上对2010年至2013年间发表的临床研究进行了详细的文献检索。关键检索词包括“儿童血脂异常/高脂血症”、“心血管疾病”、“动脉粥样硬化”、“家族性高胆固醇血症”、“高甘油三酯血症”和“糖尿病”。还对这些出版物的其他参考文献进行了回顾。最终选取了与该主题相关的出版物。
这些指南包含了多项与血脂管理相关的重要建议,包括在9至11岁时对所有儿童进行非空腹非高密度脂蛋白胆固醇筛查,采用积极的生活方式改变以达到胆固醇目标,以及对低密度脂蛋白胆固醇升高的患者启动他汀类药物治疗。此外,1型和2型糖尿病现在都被视为高危疾病,并设有严格的胆固醇目标。主要目的是早期识别家族性高胆固醇血症患儿;然而,这些建议也引发了一些争议。本次更新的目的是总结这些最新的血脂指南,介绍相关争议,突出常见的胆固醇疾病,并讨论儿童糖尿病患者特有的血脂异常。
识别和治疗血脂异常的青少年对于降低未来心血管疾病至关重要。提高对最新NHLBI指南的理解和应用对于改善心血管疾病结局至关重要。